AbbVie Inc.

AbbVie Inc. (ABBV) Stock Analysis

$255.480

-2.631 (-1.03%)At close

Loading chart…
High
259.000
Open
258.670
VWAP
256.52
Vol
3.22M
Mkt Cap
298.41B
Low
255.080
Amount
827.24M
EV/EBITDA, TTM
13.95

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.

www.abbvie.com

AI analysis of AbbVie Inc. (ABBV)

buy

AbbVie Inc is a good buy right now due to its recent positive developments and strong financial indicators. The current price is $255.48, and the company has a forward P/E ratio of 18.69, indicating a reasonable valuation compared to its earnings potential. Additionally, AbbVie has raised its dividends for 54 consecutive years, with a recent payout of $1.73 per share, yielding 2.6%, which is attractive for long-term investors. However, the RSI is currently at 38.91, suggesting that the stock is approaching oversold territory, which could present a buying opportunity.

Analyst Ratings (20)

-1.36% downside
Buy
10 Buy
10 Hold
0 Sell
Current: 255.48
Low
223.00
Average
252.00
High
289.00

Piper Sandler

2026-08-20

Price Target

$303

Overweight

Wolfe Research

2026-08-13

Price Target

$300

Outperform

Erste Group

2026-08-05

Price Target

—

Buy

Guggenheim

2026-08-04

Price Target

$288

Buy

Cantor Fitzgerald

2026-08-03

Price Target

$285

Overweight
See All Ratings

Valuation Metrics

The current forward P/E ratio for AbbVie Inc. (ABBV) is 18.69, compared to its 5-year average forward P/E of 14.00.

Forward P/E

Overvalued
5Y Average P/E
14.00
Current P/E
18.69
Overvalued
16.61
Undervalued
11.39

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
13.15
Current EV/EBITDA
13.95
Overvalued
16.14
Undervalued
10.16

Forward P/S

Overvalued
5Y Average P/S
5.12
Current P/S
6.20
Overvalued
5.85
Undervalued
4.40

Alphio AI Price Scenarios for ABBV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ABBV

$230.51

Scenario price

B

Base

Base · 50%ABBV

$200.19

Scenario price

B

Bear

Bear · 25%ABBV

$199.82

Scenario price

Whales holding ABBV

B

Barclays Bank Plc

+ HoldingABBV

+2.67%

3M Return

S

Sanders Capital, LLC

+ HoldingABBV

+0.96%

3M Return

S

Stifel Asset Management Corp.

+ HoldingABBV

+0.51%

3M Return

A

AP Fonden 7

+ HoldingABBV

+0.28%

3M Return

M

Marshall Wace LLP

+ HoldingABBV

+0.07%

3M Return

R

Royal London Asset Management Ltd.

+ HoldingABBV

+0.02%

3M Return

Events Timeline

2026-08-27 (ET)

05:30:00

AbbVie Submits Skyrizi Application to EMA for Crohn's Disease Treatment

2026-08-26 (ET)

10:30:00

Canada Raises Tariffs on U.S. Steel and Aluminum to 50%

2026-08-04 (ET)

10:00:00

Allergan Aesthetics Submits Botox Cosmetic Application for Review

08:30:00

Allergan Aesthetics' Botox Cosmetic Application Accepted for FDA Review

Show More Events

News

Show More News

ABBV FAQ — answered by Alphio AI

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

AbbVie Inc is a good buy right now due to its recent positive developments and strong financial indicators. The current price is $255.48, and the company has a forward P/E ratio of 18.69, indicating a reasonable valuation compared to its earnings potential. Additionally, AbbVie has raised its dividends for 54 consecutive years, with a recent payout of $1.73 per share, yielding 2.6%, which is attractive for long-term investors. However, the RSI is currently at 38.91, suggesting that the stock is approaching oversold territory, which could present a buying opportunity.

20 analysts cover ABBV: 10 rate it Buy, 10 Hold and 0 Sell. The average price target is 252.00.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten